Rezdiffra (resmetirom) — United Healthcare
metabolic dysfunction-associated steatohepatitis (MASH) [formerly known as nonalcoholic steatohepatitis (NASH)] with moderate to advanced liver fibrosis (fibrosis stage F2 or F3)
Initial criteria
- Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) [formerly known as nonalcoholic steatohepatitis (NASH)]
- AND Moderate to advanced liver fibrosis (fibrosis stage F2 or F3)
Reauthorization criteria
- Documentation of positive clinical response to Rezdiffra therapy
Approval duration
12 months